<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39745312</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rise in Minimally Invasive Surgery for Colorectal Cancer Is Associated With Adoption of Robotic Surgery.</ArticleTitle><Pagination><StartPage>426</StartPage><EndPage>436</EndPage><MedlinePgn>426-436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003617</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Minimally invasive surgery is associated with improved short-term outcomes and similar long-term oncologic outcomes for patients with colorectal cancer compared with open surgery. Although the robotic approach has ergonomic and technical benefits, how it has impacted the utilization of traditional laparoscopic surgery and minimally invasive surgery overall is unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Describe trends in open, robotic, and laparoscopic approaches for colorectal cancer resections and examine factors associated with minimally invasive surgery.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study using data from the National Cancer Database from 2010 to 2020.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Commission on Cancer-accredited US facilities.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients diagnosed with nonmetastatic colon or rectal adenocarcinoma.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Surgical approach rates (open, robotic, and laparoscopic).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 475,001 patients diagnosed with nonmetastatic colorectal adenocarcinoma, of whom 192,237 (40.5%) underwent open surgery, 64,945 (13.7%) underwent robotic surgery, and 217,819 (45.9%) underwent laparoscopic surgery. For colon cancer, laparoscopic minimally invasive surgery use steadily increased, with a peak prevalence of 54.0% in 2016, and total minimally invasive surgery (robotic + laparoscopic) was performed more often than open surgery from 2013 through 2020. For rectal cancer, laparoscopic minimally invasive surgery had a peak prevalence of 37.2% in 2014 and declined from 2014 through 2020; robotic surgery prevalence increased throughout the study period (5.5% in 2010, 24.7% in 2015, and 48.8% in 2020). Minimally invasive surgery use increased in facilities performing robotic surgery every year during the study period. For both colon and rectal cancer, the use of open surgery decreased across all facilities throughout the study period.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study used the National Cancer Database, which may not be generalizable to non-Commission on Cancer institutions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Minimally invasive surgery steadily increased across all facilities from 2010 through 2020. Open resections declined, laparoscopic resections plateaued, and robotic resections increased for colon and rectal cancer. Minimally invasive surgery increases may be driven by increases in robot-assisted surgery. See Video Abstract.</AbstractText><AbstractText Label="EL AUMENTO DE LA CIRUGA MNIMAMENTE INVASIVA PARA EL CNCER COLORRECTAL SE ASOCIA CON LA ADOPCIN A LA CIRUGA ROBTICA" NlmCategory="UNASSIGNED">ANTECEDENTES:La cirug&#xed;a m&#xed;nimamente invasiva se asocia con mejores resultados a corto plazo y resultados oncol&#xf3;gicos similares a largo plazo para pacientes con c&#xe1;ncer colorrectal en comparaci&#xf3;n con la cirug&#xed;a abierta. Aunque el abordaje rob&#xf3;tico tiene beneficios ergon&#xf3;micos y t&#xe9;cnicos, no est&#xe1; claro c&#xf3;mo ha afectado la utilizaci&#xf3;n de la cirug&#xed;a laparosc&#xf3;pica tradicional y la cirug&#xed;a m&#xed;nimamente invasiva en general.OBJETIVO:Describir las tendencias en los abordajes abiertos, rob&#xf3;ticos y laparosc&#xf3;picos para las resecciones de c&#xe1;ncer colorrectal y examinar los factores asociados con la cirug&#xed;a m&#xed;nimamente invasiva.DISE&#xd1;O:Estudio de cohorte retrospectivo utilizando datos de la Base de Datos Nacional del C&#xe1;ncer desde 2010 hasta 2020.ESCENARIO:Centros estadounidenses acreditados por la Comisi&#xf3;n sobre el C&#xe1;ncer.PACIENTES:Pacientes diagnosticados con adenocarcinoma de colon o recto no metast&#xe1;sico.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:Tasas de abordaje quir&#xfa;rgico (abierto, rob&#xf3;tico, laparosc&#xf3;pico).RESULTADOS:Identificamos 475.001 pacientes con diagn&#xf3;stico de adenocarcinoma colorrectal no metast&#xe1;sico, de los cuales 192.237 (40,5%) se sometieron a cirug&#xed;a abierta, 64.945 (13,7%) se sometieron a cirug&#xed;a rob&#xf3;tica y 217.819 (45,9%) se sometieron a cirug&#xed;a laparosc&#xf3;pica. Para el c&#xe1;ncer de colon, el uso de cirug&#xed;a m&#xed;nimamente invasiva laparosc&#xf3;pica aument&#xf3; de manera constante, con una prevalencia m&#xe1;xima del 54,0% en 2016, y la cirug&#xed;a m&#xed;nimamente invasiva total (rob&#xf3;tica + laparosc&#xf3;pica) se realiz&#xf3; con mayor frecuencia que la cirug&#xed;a abierta desde 2013 hasta 2020. Para el c&#xe1;ncer de recto, la cirug&#xed;a m&#xed;nimamente invasiva laparosc&#xf3;pica tuvo una prevalencia m&#xe1;xima del 37,2% en 2014 y disminuy&#xf3; desde 2014 hasta 2020; La prevalencia de la cirug&#xed;a rob&#xf3;tica aument&#xf3; durante el per&#xed;odo de estudio (5,5 % en 2010, 24,7 % en 2015, 48,8 % en 2020). El uso de cirug&#xed;a m&#xed;nimamente invasiva aument&#xf3; en los centros que realizan cirug&#xed;a rob&#xf3;tica cada a&#xf1;o durante el per&#xed;odo de estudio. Tanto para el c&#xe1;ncer de colon como para el c&#xe1;ncer de recto, el uso de cirug&#xed;a abierta disminuy&#xf3; en todos los centros durante el per&#xed;odo de estudio.LIMITACIONES:Se utiliz&#xf3; la base de datos nacional sobre el c&#xe1;ncer, que puede no ser generalizable a instituciones que no pertenecen a la Comisi&#xf3;n sobre el C&#xe1;ncer.CONCLUSIONES:La cirug&#xed;a m&#xed;nimamente invasiva aument&#xf3; de manera constante en todos los centros entre 2010 y 2020. Las resecciones abiertas disminuyeron, las resecciones laparosc&#xf3;picas se estabilizaron y las resecciones rob&#xf3;ticas aumentaron para el c&#xe1;ncer de colon y recto. Los aumentos de la cirug&#xed;a m&#xed;nimamente invasiva pueden estar impulsados por aumentos en la cirug&#xed;a asistida por robot. (Traducci&#xf3;n--Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manisundaram</LastName><ForeName>Naveen</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2532-3247</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Childers</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Chung-Yuan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uppal</LastName><ForeName>Abhineet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konishi</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarski</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peacock</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Y Nancy</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>George J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-9758-5361</Identifier><AffiliationInfo><Affiliation>Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 TR004908</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009599</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32CA009599-33</GrantID><Agency>National Institute of Health / National Cancer Institute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="Y">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>13</Day><Hour>14</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>2</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39745312</ArticleId><ArticleId IdType="mid">NIHMS2075765</ArticleId><ArticleId IdType="pmc">PMC12335190</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003617</ArticleId><ArticleId IdType="pii">00003453-990000000-00836</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021;19(3):329&#x2013;359. doi: 10.6004/jnccn.2021.0012</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2021.0012</ArticleId><ArticleId IdType="pubmed">33724754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Jemal A, Lin CC, Hu CY, Chang GJ. Comparative Effectiveness of Laparoscopy vs Open Colectomy Among Nonmetastatic Colon Cancer Patients: An Analysis Using the National Cancer Data Base. JNCI Journal of the National Cancer Institute. 2015;107(3):dju491-dju491. doi: 10.1093/jnci/dju491</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dju491</ArticleId><ArticleId IdType="pmc">PMC4565531</ArticleId><ArticleId IdType="pubmed">25663688</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005;6(7):477&#x2013;484. doi: 10.1016/S1470-2045(05)70221-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(05)70221-7</ArticleId><ArticleId IdType="pubmed">15992696</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonjer HJ, Deijen CL, Abis GA, et al. A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer. New England Journal of Medicine. 2015;372(14):1324&#x2013;1332. doi: 10.1056/NEJMoa1414882</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414882</ArticleId><ArticleId IdType="pubmed">25830422</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Outcomes of Surgical Therapy Study Group. A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer. New England Journal of Medicine. 2004;350(20):2050&#x2013;2059. doi: 10.1056/NEJMoa032651</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa032651</ArticleId><ArticleId IdType="pubmed">15141043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleshman J, Branda M, Sargent DJ, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes. JAMA. 2015;314(13):1346. doi: 10.1001/jama.2015.10529</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.10529</ArticleId><ArticleId IdType="pmc">PMC5140087</ArticleId><ArticleId IdType="pubmed">26441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Allaix ME, Rebecchi F, Fichera A. The Landmark Series: Minimally Invasive (Laparoscopic and Robotic) Colorectal Cancer Surgery. Ann Surg Oncol. 2020;27(10):3704&#x2013;3715. doi: 10.1245/s10434-020-08833-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-020-08833-8</ArticleId><ArticleId IdType="pubmed">32648183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J. Long-term outcome of laparoscopic surgery for colorectal cancer: A cochrane systematic review of randomised controlled trials. Cancer Treat Rev. 2008;34(6):498&#x2013;504. doi: 10.1016/j.ctrv.2008.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2008.03.011</ArticleId><ArticleId IdType="pubmed">18468803</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk W, Haase O, Neudecker JJ, M&#xfc;ller JM. Short term benefits for laparoscopic colorectal resection. Cochrane Database of Systematic Reviews. 2005;2008(4). doi: 10.1002/14651858.CD003145.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003145.pub2</ArticleId><ArticleId IdType="pmc">PMC8693724</ArticleId><ArticleId IdType="pubmed">16034888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS &#xae;) Society Recommendations: 2018. World J Surg. 2019;43(3):659&#x2013;695. doi: 10.1007/s00268-018-4844-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-018-4844-y</ArticleId><ArticleId IdType="pubmed">30426190</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitao MM, Kreaden US, Laudone V, et al. The RECOURSE Study: Long-term Oncologic Outcomes Associated With Robotically Assisted Minimally Invasive Procedures for Endometrial, Cervical, Colorectal, Lung, or Prostate Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2023;277(3):387&#x2013;396. doi: 10.1097/SLA.0000000000005698</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000005698</ArticleId><ArticleId IdType="pmc">PMC9905254</ArticleId><ArticleId IdType="pubmed">36073772</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Yuan W, Li T, et al. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7(11):991&#x2013;1004. doi: 10.1016/S2468-1253(22)00248-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(22)00248-5</ArticleId><ArticleId IdType="pubmed">36087608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Pigazzi A, Marshall H, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer. JAMA. 2017;318(16):1569. doi: 10.1001/jama.2017.7219</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.7219</ArticleId><ArticleId IdType="pmc">PMC5818805</ArticleId><ArticleId IdType="pubmed">29067426</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock O, Limvorapitak T, Bednarski BK, et al. Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective. Colorectal Disease. 2020;22(12):2049&#x2013;2056. doi: 10.1111/codi.15350</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/codi.15350</ArticleId><ArticleId IdType="pubmed">32892473</ArticleId></ArticleIdList></Reference><Reference><Citation>Childers CP, Maggard-Gibbons M. Estimation of the Acquisition and Operating Costs for Robotic Surgery. JAMA. 2018;320(8):835. doi: 10.1001/jama.2018.9219</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.9219</ArticleId><ArticleId IdType="pmc">PMC6142989</ArticleId><ArticleId IdType="pubmed">30167686</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbash GI, Glied SA. New Technology and Health Care Costs &#x2014; The Case of Robot-Assisted Surgery. New England Journal of Medicine. 2010;363(8):701&#x2013;704. doi: 10.1056/NEJMp1006602</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1006602</ArticleId><ArticleId IdType="pubmed">20818872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam MS, Kaoutzanis C, Mullard AJ, et al. A population-based study comparing laparoscopic and robotic outcomes in colorectal surgery. Surg Endosc. 2016;30(2):455&#x2013;463. doi: 10.1007/s00464-015-4218-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-015-4218-6</ArticleId><ArticleId IdType="pubmed">25894448</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu I, Fingar KR, Cutler E, Guo J, Jiang HJ. Comparison of 3 Safety-Net Hospital Definitions and Association With Hospital Characteristics. JAMA Netw Open. 2019;2(8):e198577. doi: 10.1001/jamanetworkopen.2019.8577</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.8577</ArticleId><ArticleId IdType="pmc">PMC6686776</ArticleId><ArticleId IdType="pubmed">31390034</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453&#x2013;1457. doi: 10.1016/S0140-6736(07)61602-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn RS, Wima K, Vestal MA, et al. Effect of hospital safety-net burden on cost and outcomes after surgery. JAMA Surg. 2016;151(2):120&#x2013;128. doi: 10.1001/jamasurg.2015.3209</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2015.3209</ArticleId><ArticleId IdType="pubmed">26466334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakeam E, Hevelone ND, Maine R, et al. Failure to Rescue in Safety-Net Hospitals. JAMA Surg. 2014;149(3):229. doi: 10.1001/jamasurg.2013.3566</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2013.3566</ArticleId><ArticleId IdType="pubmed">24430015</ArticleId></ArticleIdList></Reference><Reference><Citation>An L, Hwang KS, Park SH, et al. Trends of robotic-assisted surgery for thyroid, colorectal, stomach and hepatopancreaticobiliary cancer: 10 year Korea trend investigation. Asian J Surg. 2021;44(1):199&#x2013;205. doi: 10.1016/j.asjsur.2020.05.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asjsur.2020.05.029</ArticleId><ArticleId IdType="pubmed">32571714</ArticleId></ArticleIdList></Reference><Reference><Citation>Giesen LJX, Dekker JWT, Verseveld M, et al. Implementation of robotic rectal cancer surgery: a cross-sectional nationwide study. Surg Endosc. 2023;37(2):912&#x2013;920. doi: 10.1007/s00464-022-09568-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-022-09568-1</ArticleId><ArticleId IdType="pmc">PMC9945537</ArticleId><ArticleId IdType="pubmed">36042043</ArticleId></ArticleIdList></Reference><Reference><Citation>Larach JT, Flynn J, Kong J, et al. Robotic colorectal surgery in Australia: evolution over a decade. ANZ J Surg. 2021;91(11):2330&#x2013;2336. doi: 10.1111/ans.16554</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.16554</ArticleId><ArticleId IdType="pubmed">33438361</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock O, Limvorapitak T, Hu CY, et al. Robotic rectal cancer surgery: comparative study of the impact of obesity on early outcomes. Br J Surg. 2020;107(12):1552&#x2013;1557. doi: 10.1002/bjs.12023</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.12023</ArticleId><ArticleId IdType="pmc">PMC7938826</ArticleId><ArticleId IdType="pubmed">32996597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheetz KH, Norton EC, Dimick JB, Regenbogen SE. Perioperative Outcomes and Trends in the Use of Robotic Colectomy for Medicare Beneficiaries From 2010 Through 2016. JAMA Surg. 2020;155(1):41. doi: 10.1001/jamasurg.2019.4083</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2019.4083</ArticleId><ArticleId IdType="pmc">PMC6802268</ArticleId><ArticleId IdType="pubmed">31617874</ArticleId></ArticleIdList></Reference><Reference><Citation>Warps AK, Saraste D, Westerterp M, et al. National differences in implementation of minimally invasive surgery for colorectal cancer and the influence on short-term outcomes. Surg Endosc. 2022;36(8):5986&#x2013;6001. doi: 10.1007/s00464-021-08974-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-021-08974-1</ArticleId><ArticleId IdType="pmc">PMC9283170</ArticleId><ArticleId IdType="pubmed">35258664</ArticleId></ArticleIdList></Reference><Reference><Citation>Horsey ML, Parascandola SA, Sparks AD, Hota S, Ng M, Obias V. The impact of surgical approach on short- and long-term outcomes after rectal cancer resection in elderly patients: a national cancer database propensity score matched comparison of robotic, laparoscopic, and open approaches. Surg Endosc. 2022;36(2):1269&#x2013;1277. doi: 10.1007/s00464-021-08401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-021-08401-5</ArticleId><ArticleId IdType="pubmed">33638109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Park SC, Park JW, et al. Robot-assisted Versus Laparoscopic Surgery for Rectal Cancer. Ann Surg. 2018;267(2):243&#x2013;251. doi: 10.1097/SLA.0000000000002321</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002321</ArticleId><ArticleId IdType="pubmed">28549014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wei Z, Bie M, Peng X, Chen C. Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis. Surg Endosc. 2016;30(12):5601&#x2013;5614. doi: 10.1007/s00464-016-4892-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-016-4892-z</ArticleId><ArticleId IdType="pubmed">27402096</ArticleId></ArticleIdList></Reference><Reference><Citation>Trastulli S, Farinella E, Cirocchi R, et al. Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta&#x2010;analysis of short&#x2010;term outcome. Colorectal Disease. 2012;14(4). doi: 10.1111/j.1463-1318.2011.02907.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1318.2011.02907.x</ArticleId><ArticleId IdType="pubmed">22151033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel MK, Al-Qudah G, Shchatsko A, et al. Robotic Approach is Associated With a Lower Conversion Rate Compared to Laparoscopic Approach for Patients Undergoing Colectomy for T4b Colon Cancer. An Analysis of the National Cancer Database. Surg Innov. 2023;30(2):193&#x2013;200. doi: 10.1177/15533506221125323</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15533506221125323</ArticleId><ArticleId IdType="pubmed">36069752</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrie J, Jayne DG, Wright J, Murray CJC, Collinson FJ, Pavitt SH. Attaining Surgical Competency and Its Implications in Surgical Clinical Trial Design: A Systematic Review of the Learning Curve in Laparoscopic and Robot-Assisted Laparoscopic Colorectal Cancer Surgery. Ann Surg Oncol. 2014;21(3):829&#x2013;840. doi: 10.1245/s10434-013-3348-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-013-3348-0</ArticleId><ArticleId IdType="pubmed">24217787</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid TG, Kini M, Ind TEJ. Comparing the learning curve for robotically assisted and straight stick laparoscopic procedures in surgical novices. The International Journal of Medical Robotics and Computer Assisted Surgery. 2010;6(3):306&#x2013;310. doi: 10.1002/rcs.333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcs.333</ArticleId><ArticleId IdType="pubmed">20533536</ArticleId></ArticleIdList></Reference><Reference><Citation>Melich G, Hong YK, Kim J, et al. Simultaneous development of laparoscopy and robotics provides acceptable perioperative outcomes and shows robotics to have a faster learning curve and to be overall faster in rectal cancer surgery: analysis of novice MIS surgeon learning curves. Surg Endosc. 2015;29(3):558&#x2013;568. doi: 10.1007/s00464-014-3698-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-014-3698-0</ArticleId><ArticleId IdType="pubmed">25030474</ArticleId></ArticleIdList></Reference><Reference><Citation>Odermatt M, Ahmed J, Panteleimonitis S, Khan J, Parvaiz A. Prior experience in laparoscopic rectal surgery can minimise the learning curve for robotic rectal resections: a cumulative sum analysis. Surg Endosc. 2017;31(10):4067&#x2013;4076. doi: 10.1007/s00464-017-5453-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-017-5453-9</ArticleId><ArticleId IdType="pubmed">28271267</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson ARL, Solomon MJ, Lumley JW, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer. JAMA. 2015;314(13):1356. doi: 10.1001/jama.2015.12009</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.12009</ArticleId><ArticleId IdType="pubmed">26441180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciardi R, Goldstone RN, Francone T, et al. Healthcare Resource Utilization After Surgical Treatment of Cancer: Value of Minimally Invasive Surgery. Surg Endosc. 2022;36(10):7549&#x2013;7560. doi: 10.1007/s00464-022-09189-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-022-09189-8</ArticleId><ArticleId IdType="pmc">PMC9022614</ArticleId><ArticleId IdType="pubmed">35445834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37594896</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Tumor Marker Trajectories and Survival Analysis in Patients With Normal Carcinoembryonic Antigen Ranges After Colorectal Cancer Resection.</ArticleTitle><Pagination><StartPage>62</StartPage><EndPage>72</EndPage><MedlinePgn>62-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002894</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence regarding postoperative CEA for predicting long-term outcomes of colorectal cancer remains controversial, especially in patients with normal postoperative CEA.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the risk difference among different postoperative CEA trajectories in patients with normal postoperative CEA after curative colorectal cancer resection.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This cohort study was conducted at a comprehensive cancer center and included data retrieved from a prospectively collected database between January 2006 and December 2018.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with colorectal cancer who underwent surgery for primary stage I to III colorectal adenocarcinoma were included and those with postoperative CEA &gt;5&#x2009;ng/mL were excluded.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Standard curative radical resection was performed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Ten-year overall survival and disease-free survival were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study population (n = 8156) was categorized into 6 trajectories: persistent-ultralow (n = 2351), persistent-low (n = 2474), gradually decrease (n = 401), persistent-medium (n = 1727), slightly increase (n = 909), and around-upper-limit (n = 394). The median follow-up time was 7.8 years, and the median time frame in which CEA was measured to determine trajectory was 2.6 years. The persistent-ultralow group had the highest 10-year overall survival (85.1%) and disease-free survival (82.7%). The around-upper-limit group had the lowest 10-year overall survival (55.5%) and disease-free survival (53.4%). The adjusted HR trend was comparable to the crude HR of the persistent-ultralow group. Consequently, the higher initial serum CEA groups had higher HRs of overall survival and disease-free survival. The adjusted HR of overall survival was 2.96 (95% CI, 2.39-3.66) and of disease-free survival was 2.66 (95% CI, 2.18-3.69) for the around-upper-limit groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The postoperative serum CEA trajectory is an independent factor associated with long-term outcomes. Although CEA levels were all within normal range, higher levels of postoperative serum CEA trajectory correlated with worse long-term oncological outcomes. See Video Abstract.</AbstractText><AbstractText Label="TRAYECTORIAS DE MARCADORES TUMORALES Y ANLISIS DE SUPERVIVENCIA EN PACIENTES CON RANGOS NORMALES DE ANTGENO CARCINOEMBRIONARIO POSTERIOR A RESECCIN DE CNCER COLORRECTAL" NlmCategory="UNASSIGNED">ANTECEDENTES:La evidencia sobre el CEA post operatorio para la predicci&#xf3;n de los resultados a largo plazo del c&#xe1;ncer colorrectal sigue siendo controversial, especialmente en pacientes con CEA post quir&#xfa;rgico normal.OBJETIVO:Investigar la diferencia de riesgo entre diferentes trayectorias postoperatorias del CEA en pacientes con CEA post quir&#xfa;rgico normal tras la resecci&#xf3;n curativa del c&#xe1;ncer colorrectal.DISE&#xd1;O:Este estudio de cohorte se realiz&#xf3; en un centro oncol&#xf3;gico integral e incluy&#xf3; datos recuperados de una base de datos recopilada prospectivamente entre enero de 2006 y diciembre de 2018.AJUSTES:Estudio de cohorte retrospectivo.PACIENTES:Se incluyeron pacientes con el diagnostico de CCR que fueron sometidos a cirug&#xed;a por adenocarcinoma colorrectal primario en estadio I-III. Se excluyeron pacientes con CEA postoperatorio &gt;5&#x2009;ng/mL.INTERVENCIONES:Se realiz&#xf3; una resecci&#xf3;n radical curativa estandarizada.PRINCIPALES MEDIDAS DE RESULTADO:Se analizaron la supervivencia general a diez a&#xf1;os y la supervivencia libre de enfermedad.RESULTADOS:La poblaci&#xf3;n de estudio (n = 8156) fue clasificada en seis trayectorias, que incluyeron ultrabajo persistente (n = 2351), bajo persistente (n = 2474), disminuci&#xf3;n gradual (n = 401), medio persistente (n = 1727), aumento leve (n = 909) y alrededor del l&#xed;mite superior (n = 394). La mediana del tiempo de seguimiento fue de 7,8 a&#xf1;os y la mediana del per&#xed;odo de tiempo en el que el CEA fue medido para determinar la trayectoria fue de 2,6 a&#xf1;os. El grupo ultrabajo persistente tuvo la mayor supervivencia general a 10 a&#xf1;os (85,1 %) y supervivencia libre de enfermedad (82,7 %). El grupo alrededor del l&#xed;mite superior tuvo la supervivencia general a 10 a&#xf1;os m&#xe1;s baja (55,5 %) y la supervivencia libre de enfermedad (53,4 %). La tendencia del &#xed;ndice de riesgo ajustado fue comparable al &#xed;ndice de riesgo bruto del grupo ultrabajo persistente. En consecuencia, los grupos con CEA s&#xe9;rico iniciales m&#xe1;s altos ten&#xed;an &#xed;ndices de riesgos m&#xe1;s altos de supervivencia general y supervivencia libre de enfermedad. Los &#xed;ndices de riesgos ajustados de supervivencia general/supervivencia libre de enfermedad fueron 2,96/2,66 (intervalo de confianza del 95 %: 2,39-3,66/2,18-3,69) para los grupos cercanos al l&#xed;mite superior.LIMITACIONES:El estudio estuvo limitado por su dise&#xf1;o retrospectivo.CONCLUSIONES:La trayectoria del CEA s&#xe9;rico postoperatorio es un factor independiente asociado con resultados a largo plazo. Aunque los niveles de CEA se encontraban todos dentro del rango normal, los niveles m&#xe1;s altos de trayectoria del CEA en suero posoperatorio se correlacionaron con peores resultados oncol&#xf3;gicos a largo plazo. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Yih-Jong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Hsin-Yin</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei MacKay Memorial Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Yu-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Le-Yin</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program of Data Science, National Taiwan University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wen-Sy</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chun-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jong</LastName><ForeName>Bor-Kang</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Jeng-Fu</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37594896</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002894</ArticleId><ArticleId IdType="pii">00003453-202401000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzmaurice C, Abate D, Abbasi N, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749&#x2013;1768.</Citation></Reference><Reference><Citation>Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4:309&#x2013;315.</Citation></Reference><Reference><Citation>Ramphal W, Boeding JRE, van Iwaarden M, et al. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. Int J Biol Markers. 2019;34:60&#x2013;68.</Citation></Reference><Reference><Citation>Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943&#x2013;947.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 2.2023. NCCN; 2023. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf .</Citation></Reference><Reference><Citation>Argiles G, Tabernero J, Labianca R, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291&#x2013;1305.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Moranta F, Sal&#xf3; J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386&#x2013;393.</Citation></Reference><Reference><Citation>Bhatti I, Patel M, Dennison AR, Thomas MW, Garcea G. Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg. 2015;16:123&#x2013;128.</Citation></Reference><Reference><Citation>Primrose JN, Perera R, Gray A, et al.; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263&#x2013;270.</Citation></Reference><Reference><Citation>K&#xf6;rner H, S&#xf6;reide K, Stokkeland PJ, S&#xf6;reide JA. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol. 2007;14:417&#x2013;423.</Citation></Reference><Reference><Citation>Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence&#x2014;a systematic review. Int J Surg. 2016;25:134&#x2013;144.</Citation></Reference><Reference><Citation>Hung H, You J, Chiang J, et al. Why recurrence was initially suspected during colorectal cancer postoperative surveillance?: a retrospective analysis. Medicine (Baltim). 2020;99:e22803.</Citation></Reference><Reference><Citation>Verberne CJ, Zhan Z, van den Heuvel E, et al. Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging: results of the randomized &#x201c;CEAwatch&#x201d; trial. Eur J Surg Oncol. 2015;41:1188&#x2013;1196.</Citation></Reference><Reference><Citation>Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645&#x2013;650.</Citation></Reference><Reference><Citation>Nakamura Y, Shida D, Tanabe T, et al. Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer. Cancer Med. 2020;9:653&#x2013;662.</Citation></Reference><Reference><Citation>Shinkins B, Primrose JN, Pugh SA, et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. Br J Surg. 2018;105:658&#x2013;662.</Citation></Reference><Reference><Citation>Li C, Zhang D, Pang X, et al. Trajectories of perioperative serum tumor markers and colorectal cancer outcomes: a retrospective, multicenter longitudinal cohort study. EBioMedicine. 2021;74:103706.</Citation></Reference><Reference><Citation>Yakabe T, Nakafusa Y, Sumi K, et al. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol. 2010;17:2349&#x2013;2356.</Citation></Reference><Reference><Citation>Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65:205&#x2013;210.</Citation></Reference><Reference><Citation>Nagin DS, Odgers CL. Group-based trajectory modeling (nearly) two decades later. J Quant Criminol. 2010;26:445&#x2013;453.</Citation></Reference><Reference><Citation>Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35:542&#x2013;571.</Citation></Reference><Reference><Citation>Nagin DS, Jones BL, Passos VL, Tremblay RE. Group-based multi-trajectory modeling. Stat Methods Med Res. 2018;27:2015&#x2013;2023.</Citation></Reference><Reference><Citation>McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32:3388&#x2013;3414.</Citation></Reference><Reference><Citation>Tein JY, Mazza GL, Gunn HJ, et al. Multigroup propensity score approach to evaluating an effectiveness trial of the new beginnings program. Eval Health Prof. 2018;41:290&#x2013;320.</Citation></Reference><Reference><Citation>Moran AE, Liu K. Invited commentary: quantifying the added value of repeated measurements. Am J Epidemiol. 2017;186:908&#x2013;909.</Citation></Reference><Reference><Citation>Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109&#x2013;138.</Citation></Reference><Reference><Citation>Dayimu A, Wang C, Li J, et al. Trajectories of lipids profile and incident cardiovascular disease risk: a longitudinal cohort study. J Am Heart Assoc. 2019;8:e013479.</Citation></Reference><Reference><Citation>Raghavan S, Liu WG, Berkowitz SA, et al. Association of glycemic control trajectory with short-term mortality in diabetes patients with high cardiovascular risk: a joint latent class modeling study. J Gen Intern Med. 2020;35:2266&#x2013;2273.</Citation></Reference><Reference><Citation>Ke C, Stukel TA, Shah BR, et al. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: a population-based observational study. PLoS Med. 2020;17:e1003316.</Citation></Reference><Reference><Citation>Li Z, Li C, Pu H, et al. Trajectories of perioperative serum carcinoembryonic antigen and colorectal cancer outcome: a retrospective, multicenter longitudinal cohort study. Clin Transl Med. 2021;11:e293.</Citation></Reference><Reference><Citation>Suzuki Y, Ogura A, Uehara K, et al. The carcinoembryonic antigen ratio is a potential predictor of survival in recurrent colorectal cancer. Int J Clin Oncol. 2021;26:1264&#x2013;1271.</Citation></Reference><Reference><Citation>Lee WS, Baek JH, Kim KK, Park YH. The prognostic significant of percentage drop in serum CEA post curative resection for colon cancer. Surg Oncol. 2012;21:45&#x2013;51.</Citation></Reference><Reference><Citation>Beom SH, Shin SJ, Kim CG, et al. Clinical significance of preoperative serum carcinoembryonic antigen within the normal range in colorectal cancer patients undergoing curative resection. Ann Surg Oncol. 2020;27:2774&#x2013;2783.</Citation></Reference><Reference><Citation>Huh JW, Kim CH, Lim SW, Kim HR, Kim YJ. Factors predicting long-term survival in colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. J Cancer Res Clin Oncol. 2013;139:1449&#x2013;1455.</Citation></Reference><Reference><Citation>Fenqi D, Yupeng L, Qiuju Z, et al. Early postoperative serum carcinoembryonic antigen is a stronger independent prognostic factor for stage II colorectal cancer patients than T4 stage and preoperative CEA. Front Oncol. 2021;11:758509.</Citation></Reference><Reference><Citation>Lan YT, Lin JK, Lin TC, et al. Prognostic significance of perioperative change of CEA level in colorectal patients when pre-operative level is normal. Hepatogastroenterology. 2012;59:717&#x2013;720.</Citation></Reference><Reference><Citation>Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis. 2007;9:527&#x2013;531.</Citation></Reference><Reference><Citation>Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. Ann Surg Oncol. 2012;19:3422&#x2013;3431.</Citation></Reference><Reference><Citation>Lin PC, Lin JK, Lin CC, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012;27:1333&#x2013;1338.</Citation></Reference><Reference><Citation>Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res. 2007;13:2406&#x2013;2413.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33315717</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Excellent Outcomes After Extended Radical Pelvic Resection for Locally Advanced and Recurrent IBD-Associated Anorectal Cancer.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>216</EndPage><MedlinePgn>209-216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001744</ELocationID><Abstract><AbstractText Label="BACKGROUND">Anorectal cancer arising in IBD can be challenging to manage. There is a paucity of reports describing locally advanced and recurrent anorectal cancer in this setting.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to describe patients who underwent extended radical pelvic resection for locally advanced and recurrent IBD-associated anorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective review of a prospectively maintained database of extended radical pelvic resection.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a quaternary pelvic malignancy referral center.</AbstractText><AbstractText Label="PATIENTS">All of the patients who underwent extended radical pelvic resection for IBD-associated anorectal cancer between September 1994 and September 2019 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Demographic, operative, and oncologic outcomes were assessed.</AbstractText><AbstractText Label="RESULTS">Ten patients (1.3%) were identified of 765 (6 men; median age = 51 y). The average time from the diagnosis of IBD to cancer was 23 years. Five patients had surgery for primary cancer previously. All of the patients had previous complex abdominal and perineal surgical interventions. There were 7 adenocarcinomas and 3 squamous cell carcinomas. Nine underwent pelvic exenteration and 1 rectal resection with radical vaginectomy. The median operating time, intraoperative blood loss, and blood transfusion were 698 minutes, 1.8&#x2009;L, and 4.5 units. The median hospital stay was 24 days. The operative mortality and morbidity rates were 0% and 60%. At a median follow-up of 51.3 months, 7 patients remained alive and free of cancer.</AbstractText><AbstractText Label="LIMITATIONS">This is a retrospective study of a small number of patients.</AbstractText><AbstractText Label="CONCLUSIONS">Extended radical pelvic resection offers a potential cure for locally advanced and recurrent IBD-associated anorectal cancer with acceptable operative mortality and morbidity rates. A high index of suspicion is required to achieve early diagnosis. Multiple factors need to be considered in the multimodal treatment of such complex patients. See Video Abstract at http://links.lww.com/DCR/B418.</AbstractText><AbstractText Label="EXCELENTES RESULTADOS DESPUS DE LA RESECCIN PLVICA RADICAL EXTENDIDA POR CNCER ANORRECTAL RECURRENTE Y LOCALMENTE AVANZADA, ASOCIADA A ENFERMEDAD INFLAMATORIA INTESTINAL">ANTECEDENTES:C&#xe1;ncer anorrectal surgiendo de la enfermedad inflamatoria intestinal, puede ser dif&#xed;cil de manejar. Hay escasez de informes que describan el c&#xe1;ncer anorrectal localmente avanzado y recurrente en este contexto.OBJETIVO:El estudio tiene como objetivo, describir a los pacientes que se sometieron a resecci&#xf3;n p&#xe9;lvica radical extendida por c&#xe1;ncer anorrectal recurrente y localmente avanzada, asociada con enfermedad inflamatoria intestinal.DISE&#xd1;O:Esta es una revisi&#xf3;n retrospectiva, de una base de datos mantenida prospectivamente de resecci&#xf3;n p&#xe9;lvica radical extendida.AJUSTES:El estudio se realiz&#xf3; en un centro de referencia cuaternaria en malignidad p&#xe9;lvica.PACIENTES:Se incluyeron a todos los pacientes sometidos a resecci&#xf3;n p&#xe9;lvica radical ampliada por c&#xe1;ncer anorrectal, asociada a enfermedad inflamatoria intestinal entre septiembre de 1994 y septiembre de 2019.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron los resultados demogr&#xe1;ficos, quir&#xf9;rgicos y oncol&#xf3;gicos.RESULTADOS:Diez pacientes (1.3%) fueron identificados de 765 (seis masculinos; mediana de edad 51 a&#xf1;os). El tiempo promedio desde el diagn&#xf3;stico de la enfermedad inflamatoria intestinal hasta el c&#xe1;ncer, fue de 23 a&#xf1;os. Cinco pacientes fueron previamente sometidos a cirug&#xed;a por c&#xe1;ncer primario. Todos los pacientes tuvieron previamente, intervenciones quir&#xfa;rgicas abdominales y perineales complejas. Hubo siete adenocarcinomas y tres carcinomas de c&#xe9;lulas escamosas. Nueve se sometieron a exenteraci&#xf3;n p&#xe9;lvica y una a resecci&#xf3;n rectal con vaginectom&#xed;a radical. La mediana del tiempo de operaci&#xf3;n, p&#xe9;rdida de sangre intraoperatoria y transfusi&#xf3;n sangu&#xed;nea, fueron 698 minutos, 1.8 litros y 4.5 unidades respectivamente. La mediana de la estancia hospitalaria fue de 24 d&#xed;as. Las tasas de mortalidad y morbilidad operatoria fueron 0% y 60% respectivamente. En una mediana de seguimiento de 51,3 meses, siete pacientes permanecieron vivos y libres de c&#xe1;ncer.LIMITACIONES:Es un estudio retrospectivo con n&#xfa;mero peque&#xf1;o de pacientes.CONCLUSIONES:La resecci&#xf3;n p&#xe9;lvica radical extendida, ofrece una cura potencial para el c&#xe1;ncer anorrectal recurrente y localmente avanzada, asociada a0 enfermedad inflamatoria intestinal y con tasas aceptables de mortalidad y morbilidad operatoria. Se requiere un alto &#xed;ndice de sospecha para obtener un diagn&#xf3;stico temprano. Se deben considerar m&#xfa;ltiples factores en el tratamiento multimodal de pacientes tan complejos. Consulte Video Resumen en http://links.lww.com/DCR/B418. (Traducci&#xf3;n-Dr Fidel Ruiz Healy).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kah Hoong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chris O'Brien Lifehouse Cancer Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kilian G M</ForeName><Initials>KGM</Initials><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Academic Surgery at Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen Lau</LastName><ForeName>Yee</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chris O'Brien Lifehouse Cancer Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chris O'Brien Lifehouse Cancer Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Outcomes Research Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Academic Surgery at Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010385" MajorTopicYN="Y">Pelvic Exenteration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33315717</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001744</ArticleId><ArticleId IdType="pii">00003453-202102000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non -specific) Am J Med Sci. 1925;170:220&#x2013;228.</Citation></Reference><Reference><Citation>Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526&#x2013;535.</Citation></Reference><Reference><Citation>Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn&#x2019;s disease: a meta-analysis. J Gastrointest Surg. 2011;15:576&#x2013;583.</Citation></Reference><Reference><Citation>Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53&#x2013;61.</Citation></Reference><Reference><Citation>Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990;323:1228&#x2013;1233.</Citation></Reference><Reference><Citation>Levin B. Inflammatory bowel disease and colon cancer. Cancer. 1992;705 Suppl1313&#x2013;1316.</Citation></Reference><Reference><Citation>Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030&#x2013;1038.</Citation></Reference><Reference><Citation>Fornaro R, Caratto M, Caratto E, et al. Colorectal cancer in patients with inflammatory bowel disease: the need for a real surveillance program. Clin Colorectal Cancer. 2016;15:204&#x2013;212.</Citation></Reference><Reference><Citation>Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854&#x2013;862.</Citation></Reference><Reference><Citation>Hellers G, Bergstrand O, Ewerth S, Holmstr&#xf6;m B. Occurrence and outcome after primary treatment of anal fistulae in Crohn&#x2019;s disease. Gut. 1980;21:525&#x2013;527.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Baars JE, Kuipers EJ, Dijkstra G, et al.; Initiative for Crohn and Colitis. Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from the Netherlands. Scand J Gastroenterol. 2011;46:319&#x2013;325.</Citation></Reference><Reference><Citation>Shwaartz C, Munger JA, Deliz JR, et al. Fistula-associated anorectal cancer in the setting of Crohn&#x2019;s disease. Dis Colon Rectum. 2016;59:1168&#x2013;1173.</Citation></Reference><Reference><Citation>Abel ME, Chiu YS, Russell TR, Volpe PA. Adenocarcinoma of the anal glands: results of a survey. Dis Colon Rectum. 1993;36:383&#x2013;387.</Citation></Reference><Reference><Citation>Pai VD, Jatal S, Engineer R, Ostwal V, Saklani AP. Multidisciplinary management of colorectal adenocarcinoma associated with anal fistula: an Indian series. Colorectal Dis. 2015;17:O240&#x2013;O246.</Citation></Reference><Reference><Citation>Koh CE, Solomon MJ, Brown KG, et al. The evolution of pelvic exenteration practice at a single center: lessons learned from over 500 cases. Dis Colon Rectum. 2017;60:627&#x2013;635.</Citation></Reference><Reference><Citation>Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187&#x2013;196.</Citation></Reference><Reference><Citation>Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 2002.6th edSpringer-Verlag;</Citation></Reference><Reference><Citation>Amin MB, Edge S, Greene F, et al, eds. AJCC Cancer Staging Manual. 2017.8th edSpringer International Publishing: American Joint Commission on Cancer;</Citation></Reference><Reference><Citation>Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Colorectal Dis. 2012;14:1479&#x2013;1482.</Citation></Reference><Reference><Citation>Solomon MJ, Brown KGM. Extended radical resection: the standard of care for patients with advanced pelvic malignancy. Ann Surg Oncol. 2020;27:323&#x2013;324.</Citation></Reference><Reference><Citation>Solomon MJ, Brown KG, Koh CE, Lee P, Austin KK, Masya L. Lateral pelvic compartment excision during pelvic exenteration. Br J Surg. 2015;102:1710&#x2013;1717.</Citation></Reference><Reference><Citation>Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. Dis Colon Rectum. 2009;52:1223&#x2013;1233.</Citation></Reference><Reference><Citation>Solomon MJ, Tan KK, Bromilow RG, Al-mozany N, Lee PJ. Sacrectomy via the abdominal approach during pelvic exenteration. Dis Colon Rectum. 2014;57:272&#x2013;277.</Citation></Reference><Reference><Citation>Solomon MJ, Austin KK, Masya L, Lee P. Pubic bone excision and perineal urethrectomy for radical anterior compartment excision during pelvic exenteration. Dis Colon Rectum. 2015;58:1114&#x2013;1119.</Citation></Reference><Reference><Citation>Brown KGM, Solomon MJ, Austin KKS, Lee PJ, Stalley P. Posterior high sacral segmental disconnection prior to anterior en bloc exenteration for recurrent rectal cancer. Tech Coloproctol. 2016;20:401&#x2013;404.</Citation></Reference><Reference><Citation>Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749&#x2013;753.</Citation></Reference><Reference><Citation>Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn&#x2019;s disease: a systematic review of literature. J Gastrointest Surg. 2010;14:66&#x2013;73.</Citation></Reference><Reference><Citation>Mayer R, Wong WD, Rothenberger DA, Goldberg SM, Madoff RD. Colorectal cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum. 1999;42:343&#x2013;347.</Citation></Reference><Reference><Citation>Ou B, Zhao J, Guan S, Lu A. Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2016;61:881&#x2013;889.</Citation></Reference><Reference><Citation>Renz BW, Thasler WE, Preissler G, et al. Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg. 2013;17:981&#x2013;990.</Citation></Reference><Reference><Citation>Nielsen MB, Rasmussen PC, Lindegaard JC, Laurberg S. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis. 2012;14:1076&#x2013;1083.</Citation></Reference><Reference><Citation>Harris CA, Solomon MJ, Heriot AG, et al. The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg. 2016;264:323&#x2013;329.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32639283</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Adding Narrow-Band Imaging to Chromoendoscopy for the Evaluation of Tumor Response to Neoadjuvant Therapy in Rectal Cancer.</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>59</EndPage><MedlinePgn>53-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001699</ELocationID><Abstract><AbstractText Label="BACKGROUND">Endoscopic assessment is crucial in diagnosing clinical complete response after neoadjuvant therapy in rectal cancer.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this research was to evaluate the benefits of adding narrow-band imaging endoscopy to conventional chromoendoscopy in predicting pathologic complete response in the surgical specimen.</AbstractText><AbstractText Label="DESIGN">This was a prospective nonrandomized study.</AbstractText><AbstractText Label="SETTINGS">This was an ad hoc study of a prospective phase II trial at a single comprehensive cancer center that evaluated oncologic outcomes of a neoadjuvant therapy for rectal cancer.</AbstractText><AbstractText Label="PATIENTS">Patients with high-risk stage II to III low rectal cancer who received neoadjuvant modified folinic acid, fluorouracil, and oxaliplatin plus bevacizumab followed by chemoradiotherapy and surgery were included.</AbstractText><AbstractText Label="INTERVENTION">Tumor response after neoadjuvant therapy was evaluated using conventional white light endoscopy plus chromoendoscopy then followed by using narrow-band imaging based on a predefined diagnostic protocol.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Diagnostic accuracy for predicting pathologic complete response and inter-rater agreement between an expert and trainee endoscopists were compared between the assessments using conventional white light endoscopy plus chromoendoscopy and the assessment adding narrow-band imaging.</AbstractText><AbstractText Label="RESULTS">In total, 61 patients were eligible for the study, and 19 had pathologic complete response (31.1%). Although the addition of narrow-band imaging correctly converted the diagnosis in 3 patients, overall diagnostic improvement in predicting pathologic complete response was limited (conventional chromoendoscopy vs adding narrow-band imaging: accuracy, 70.5% vs 75.4%; sensitivity, 63.2% vs 73.7%; specificity, 73.8% vs 76.2%; positive predictive value, 52.2% vs 58.3%; and negative predictive value, 81.6% vs 86.5%). A &#x3ba; value for the inter-rater agreement improved from 0.599 to 0.756 by adding narrow-band imaging.</AbstractText><AbstractText Label="LIMITATIONS">This was a single-center study with a relatively small sample size.</AbstractText><AbstractText Label="CONCLUSIONS">Despite the limited improvement in diagnostic accuracy, adding narrow-band imaging to chromoendoscopy improved inter-rater agreement between the expert and nonexpert endoscopists. Narrow-band imaging is a reliable and promising modality for universal standardization of the diagnosis of clinical complete response. See Video Abstract at http://links.lww.com/DCR/B275. ADICI&#xd3;N DE IM&#xc1;GENES DE BANDA ESTRECHA A LA CROMOENDOSCOP&#xcd;A PARA LA EVALUACI&#xd3;N DE LA RESPUESTA TUMORAL A LA TERAPIA NEOADYUVANTE EN EL C&#xc1;NCER DE RECTO: La evaluaci&#xf3;n endosc&#xf3;pica es fundamental para valorar la respuesta cl&#xed;nica completa despu&#xe9;s de la terapia neoadyuvante en el c&#xe1;ncer de recto.Evaluar los beneficios de agregar endoscopia de imagen de banda estrecha a la cromoendoscop&#xed;a convencional para predecir la respuesta patol&#xf3;gica completa en la muestra quir&#xfa;rgica.Estudio prospectivo no aleatorizado.Un estudio ad hoc de un ensayo prospectivo de fase II en un solo centro integral de c&#xe1;ncer que evalu&#xf3; los resultados oncol&#xf3;gicos de una terapia neoadyuvante para el c&#xe1;ncer rectal.Pacientes con c&#xe1;ncer rectal bajo de alto riesgo en estadio II-III que recibieron &#xe1;cido fol&#xed;nico neoadyuvante modificado, fluorouracilo y oxaliplatino m&#xe1;s bevacizumab seguido de quimiorradioterapia y cirug&#xed;a.La respuesta tumoral despu&#xe9;s de la terapia neoadyuvante se evalu&#xf3; mediante endoscopia de luz blanca convencional m&#xe1;s cromoendoscop&#xed;a, seguido de im&#xe1;genes de banda estrecha basadas en un protocolo de diagn&#xf3;stico predefinido.La precisi&#xf3;n diagn&#xf3;stica para predecir la respuesta patol&#xf3;gica completa y el acuerdo entre evaluadores entre un experto y un endoscopista en entrenamiento se compararon entre las evaluaciones utilizando endoscopia de luz blanca convencional m&#xe1;s cromoendoscop&#xed;a y la evaluaci&#xf3;n agregando im&#xe1;genes de banda estrecha.En total, 61 pacientes fueron elegibles para el estudio, y 19 tuvieron una respuesta patol&#xf3;gica completa (31.1%). Aunque la adici&#xf3;n de im&#xe1;genes de banda estrecha convirti&#xf3; correctamente el diagn&#xf3;stico en 3 pacientes, la mejora diagn&#xf3;stica general en la predicci&#xf3;n de la respuesta patol&#xf3;gica completa fue limitada (cromoendoscop&#xed;a convencional versus adici&#xf3;n de im&#xe1;genes de banda estrecha: precisi&#xf3;n, 70.5% versus 75.4%; sensibilidad, 63.2% versus 73.7%; especificidad, 73.8% versus 76.2%; valor predictivo positivo, 52.2% versus 58.3%; y valor predictivo negativo, 81.6% versus 86.5%). Un valor de kappa para el acuerdo entre evaluadores mejor&#xf3; de 0.599 a 0.756 al agregar im&#xe1;genes de banda estrecha.Un estudio de centro &#xfa;nico con un tama&#xf1;o de muestra relativamente peque&#xf1;o.A pesar de la mejora limitada en la precisi&#xf3;n diagn&#xf3;stica, agregar im&#xe1;genes de banda estrecha a la cromoendoscop&#xed;a mejor&#xf3; el acuerdo entre evaluadores entre los endoscopistas expertos y no expertos. La imagenolog&#xed;a de banda estrecha es una modalidad confiable y prometedora para la estandarizaci&#xf3;n universal del diagn&#xf3;stico de respuesta cl&#xed;nica completa. Consulte Video Resumen en http://links.lww.com/DCR/B275.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishioka</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chino</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Shoichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igarashi</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagasaki</LastName><ForeName>Toshiya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyoshi</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagayama</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukunaga</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueno</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawachi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujisaki</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konishi</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="Y">Chemoradiotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062048" MajorTopicYN="Y">Narrow Band Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011351" MajorTopicYN="N">Proctoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32639283</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001699</ArticleId><ArticleId IdType="pii">00003453-202101000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2:501&#x2013;513.</Citation></Reference><Reference><Citation>Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11:835&#x2013;844.</Citation></Reference><Reference><Citation>Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016; 17:174&#x2013;183.</Citation></Reference><Reference><Citation>Ludmir EB, Palta M, Willett CG, Czito BG. Total neoadjuvant therapy for rectal cancer: An emerging option. Cancer. 2017; 123:1497&#x2013;1506.</Citation></Reference><Reference><Citation>Li J, Liu H, Yin J, et al. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget. 2015; 6:42354&#x2013;42361.</Citation></Reference><Reference><Citation>Ogura A, Chino A, Konishi T, et al. Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. Int J Colorectal Dis. 2015; 30:367&#x2013;373.</Citation></Reference><Reference><Citation>Chino A, Konishi T, Ogura A, et al. Endoscopic criteria to evaluate tumor response of rectal cancer to neoadjuvant chemoradiotherapy using magnifying chromoendoscopy. Eur J Surg Oncol. 2018; 44:1247&#x2013;1253.</Citation></Reference><Reference><Citation>Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004; 240:711&#x2013;717.</Citation></Reference><Reference><Citation>Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011; 29:4633&#x2013;4640.</Citation></Reference><Reference><Citation>Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015; 22:3873&#x2013;3880.</Citation></Reference><Reference><Citation>Hirata M, Tanaka S, Oka S, et al. Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc. 2007; 65:988&#x2013;995.</Citation></Reference><Reference><Citation>Sano Y, Tanaka S, Kudo SE, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc. 2016; 28:526&#x2013;533.</Citation></Reference><Reference><Citation>Atkinson NSS, Ket S, Bassett P, et al. Narrow-band imaging for detection of neoplasia at colonoscopy: a meta-analysis of data from individual patients in randomized controlled trials. Gastroenterology. 2019; 157:462&#x2013;471.</Citation></Reference><Reference><Citation>Konishi T, Shinozaki E, Murofushi K, et al. Phase II trial of neoadjuvant chemotherapy, chemoradiotherapy, and laparoscopic surgery with selective lateral node dissection for poor-risk low rectal cancer. Ann Surg Oncol. 2019; 26:2507&#x2013;2513.</Citation></Reference><Reference><Citation>Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma &#x2013; Response Assessment of Nonsurgical Treatments for Colorectal Carcinoma. 2013. Kanehara &amp; Co., Ltd: 77&#x2013;82.</Citation></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159&#x2013;174.</Citation></Reference><Reference><Citation>Minoda Y, Ogino H, Chinen T, et al. Objective validity of the Japan Narrow-Band Imaging Expert Team classification system for the differential diagnosis of colorectal polyps. Dig Endosc. 2019; 31:544&#x2013;551.</Citation></Reference><Reference><Citation>Ignjatovic A, Thomas-Gibson S, East JE, et al. Development and validation of a training module on the use of narrow-band imaging in differentiation of small adenomas from hyperplastic colorectal polyps. Gastrointest Endosc. 2011; 73:128&#x2013;133.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019; 62:802&#x2013;808.</Citation></Reference><Reference><Citation>Roxburgh CSD, Strombom P, Lynn P, et al. Role of the interval from completion of neoadjuvant therapy to surgery in postoperative morbidity in patients with locally advanced rectal cancer. Ann Surg Oncol. 2019; 26:2019&#x2013;2027.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>